MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1192/bjp.2025.13

Медицинская библиотека · The British journal of psychiatry : the journal of mental science · 2025

The DEPRE'5 study: pragmatic, multicentre, five-arm, parallel-group randomised controlled trial with blinded assessment to compare treatment strategies in major depression after a failed selective serotonin reuptake inhibitor treatment.

Pérez Víctor, Puigdemont Dolors, de Diego-Adeliño Javier, Elices Matilde, Leal Itziar, Cabello Maria, Rodriguez-Jimenez Roberto, Álvarez-Mon Miguel Ángel, García-Fernández Lorena, Aguilar García-Iturrospe Eduardo José, Escartí Maria José, Montejo Angel Luis, Montes José Manuel, Usall Judith, Gallego-Nogueras Ascensión, Lujan Elena, López-Carrilero Raquel, González-Pinto Ana, Ortiz-Jauregui Agurtzane, Blanch Jordi, Urretavizcaya Mikel, Colom Francesc, García-Campayo Javier, Ayuso-Mateos José Luis

СтатьяРандомизированное исследованиеМногоцентровое исследованиеPragmatic Clinical TrialСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for major depressive disorder (MDD), but initial outcomes can be modest.

AIMS: To compare SSRI dose optimisation with four alternative second-line strategies in MDD patients unresponsive to an SSRI.

METHOD: Of 257 participants, 51 were randomised to SSRI dose optimisation (SSRI-Opt), 46 to lithium augmentation (SSRI+Li), 48 to nortriptyline combination (SSRI+NTP), 55 to switch to venlafaxine (VEN) and 57 to problem-solving therapy (SSRI+PST). Primary outcomes were week-6 response/remission rates, assessed by blinded evaluators using the 17-item Hamilton Depression Rating Scale (HDRS-17). Changes in HDRS-17 scores, global improvement and safety outcomes were also explored. EudraCT No. 2007-002130-11.

RESULTS

Alternative second-line strategies led to higher response (28.2% v. 14.3%, odds ratio = 2.36 [95% CI 1.0-5.6], p = 0.05) and remission (16.9% v. 12.2%, odds ratio = 1.46, [95% CI 0.57-3.71], p = 0.27) rates, with greater HDRS-17 score reductions (-2.6 [95% CI -4.9 to -0.4], p = 0.021]) than SSRI-Opt. Significant/marginally significant effects were only observed in both response rates and HDRS-17 decreases for VEN (odds ratio = 2.53 [95% CI 0.94-6.80], p = 0.067; HDRS-17 difference: -2.7 [95% CI -5.5 to 0.0], p = 0.054) and for SSRI+PST (odds ratio = 2.46 [95% CI 0.92 to 6.62], p = 0.074; HDRS-17 difference: -3.1 [95% CI -5.8 to -0.3], p = 0.032). The SSRI+PST group reported the fewest adverse effects, while SSRI+NTP experienced the most (28.1% v. 75%; p < 0.01), largely mild.

CONCLUSIONS

Patients with MDD and insufficient response to SSRIs would benefit from any other second-line strategy aside from dose optimisation. With limited statistical power, switching to venlafaxine and adding psychotherapy yielded the most consistent results in the DEPRE'5 study.

Для цитирования: Pérez Víctor, Puigdemont Dolors, de Diego-Adeliño Javier, Elices Matilde, Leal Itziar, Cabello Maria, Rodriguez-Jimenez Roberto, Álvarez-Mon Miguel Ángel, García-Fernández Lorena, Aguilar García-Iturrospe Eduardo José, Escartí Maria José, Montejo Angel Luis, Montes José Manuel, Usall Judith, Gallego-Nogueras Ascensión, Lujan Elena, López-Carrilero Raquel, González-Pinto Ana, Ortiz-Jauregui Agurtzane, Blanch Jordi, Urretavizcaya Mikel, Colom Francesc, García-Campayo Javier, Ayuso-Mateos José Luis. The DEPRE'5 study: pragmatic, multicentre, five-arm, parallel-group randomised controlled trial with blinded assessment to compare treatment strategies in major depression after a failed selective serotonin reuptake inhibitor treatment.. The British journal of psychiatry : the journal of mental science. 2025. DOI: 10.1192/bjp.2025.13.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.